Jeremiah Hendricks

Jeremiah Hendricks has a diverse work experience in the field of biomedical research. Jeremiah is currently working at Prevail Therapeutics as a Senior Principal Scientist since March 2023. Prior to that, they worked as an Associate Scientist at the same company from May 2021 to March 2023.

Before joining Prevail Therapeutics, Jeremiah worked at Eli Lilly and Company as a Sr. Biologist from May 2018 to May 2021. Jeremiah was responsible for conducting research and experiments related to biology.

Jeremiah also gained experience as a Research Assistant II at Cogent Professionals from September 2017 to April 2018. Jeremiah worked on various research projects and assisted in data collection and analysis.

In addition, they worked as a Biochemist II at Eurofins Lancaster Laboratories from March 2015 to April 2018. Jeremiah was involved in biochemical analysis and performed laboratory experiments.

Jeremiah started their career as an Operations Technician at BioStorage Technologies, Inc. from April 2014 to March 2015. Jeremiah'sresponsibilities included receiving, labeling, and storing biological samples while adhering to FDA/GMP/GLP regulations.

During their undergraduate studies, Jeremiah worked as an Undergraduate Research Assistant at Indiana University School of Medicine from June 2007 to August 2008. Jeremiah conducted research on the impact of genetic polymorphisms on angiogenesis targeted cancer drugs and microRNAs that regulate the protein VEGF. Jeremiah gained skills in cell culture management, IHC, FISH, cloning, and luciferase assays.

Overall, Jeremiah Hendricks has extensive experience in biomedical research and has worked in various scientific roles, contributing to the field's advancement.

Jeremiah Hendricks earned a Bachelor's Degree in Applied Physics from Purdue University, where they studied from 2005 to 2009. Jeremiah later pursued a Master's Degree in Biochemistry and Molecular Biology at Indiana University School of Medicine from 2011 to 2014.